MetLife Investment Management LLC Buys 7,854 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

MetLife Investment Management LLC lifted its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 129.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,939 shares of the company’s stock after acquiring an additional 7,854 shares during the quarter. MetLife Investment Management LLC’s holdings in Dianthus Therapeutics were worth $382,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in Dianthus Therapeutics by 250.0% during the first quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock valued at $16,135,000 after buying an additional 384,182 shares during the period. Great Point Partners LLC boosted its stake in shares of Dianthus Therapeutics by 21.3% during the 2nd quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock worth $19,615,000 after acquiring an additional 132,929 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Dianthus Therapeutics by 142.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock valued at $4,543,000 after acquiring an additional 97,362 shares during the period. Bank of New York Mellon Corp raised its holdings in Dianthus Therapeutics by 860.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company’s stock worth $2,095,000 after purchasing an additional 72,509 shares during the period. Finally, Rhumbline Advisers bought a new position in Dianthus Therapeutics in the 2nd quarter worth $832,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Price Performance

Dianthus Therapeutics stock opened at $24.39 on Monday. Dianthus Therapeutics, Inc. has a 1-year low of $6.58 and a 1-year high of $33.77. The company’s 50-day moving average is $26.44 and its 200 day moving average is $26.53. The firm has a market capitalization of $721.87 million, a P/E ratio of -9.76 and a beta of 1.74.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The company had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. Research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on DNTH shares. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Monday, November 11th. Raymond James upped their target price on shares of Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. Finally, Oppenheimer raised their price target on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a report on Monday, November 11th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $46.43.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.